| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/05/2004 | US20040152078 Genetic engineering |
| 08/05/2004 | US20040152074 Seroreactive regions on HPV 16 proteins E1 and E2 |
| 08/05/2004 | US20040152073 Human cellular protein gastrointestinal glutathione peroxidase active materials |
| 08/05/2004 | US20040152071 Complex of transferrins or transcobalamin with viricides; prevention reproduction of virus |
| 08/05/2004 | US20040151784 Lactoferrin in the reduction of pain |
| 08/05/2004 | US20040151779 suspending an active agent-containing powder with active agent hydration less than about 10% in at least one anhydrous, aprotic, hydrophobic, non-polar, low-reactivity vehicle; useful to delivery to an animal for sustained release for long term treatment |
| 08/05/2004 | US20040151774 Therapeutic compositions for drug delivery to and through covering epithelia |
| 08/05/2004 | US20040151741 containing a sequestration agent including proteins, lipids and carbohydrates, particularly albumin; treating neuromuscular diseases and pain |
| 08/05/2004 | US20040151740 treating strabismus by administering of a neurotoxic component of a botulinum toxin free of a botulinum toxin complex protein. |
| 08/05/2004 | US20040151739 transporter and fusion protein contains a binding domain for the transporter and a modulation domain for the covalent modification of small GTP-binding proteins; transporter permits the uptake of the fusion protein in a target cell |
| 08/05/2004 | US20040151732 preventing or treating an abdominal aortic aneurysm or rupture by administering an immunosuppressive agent that inhibits T-lymphocyte reactivity with collagen I, collagen III, or epitope thereof; vaccines; determining risk for developing an AAA |
| 08/05/2004 | US20040151731 preventing or treating an abdominal aortic aneurysm or rupture by administering an immunosuppressive agent that inhibits T-lymphocyte reactivity with collagen I, collagen III, or epitope thereof; vaccines; determining risk for developing an AAA |
| 08/05/2004 | US20040151728 fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide; antigen bearing target such as viral, bacterial, or fungal cells, parasites or prions |
| 08/05/2004 | US20040151725 nucleic acid encoding a peptide with a CTLA4 extracellular domain and a peptide with an an immunoglobulin constant region; hinge region is modified to reduce complement activation or Fc receptor interaction; immunosuppressants |
| 08/05/2004 | US20040151723 specific to cancerous and precancerous lesions of the uterus |
| 08/05/2004 | US20040151720 Cell surface molecule mediating cell adhesion and signal transmission |
| 08/05/2004 | US20040151719 Human G-protein chemokine receptor (CCR5) HDGNR10 |
| 08/05/2004 | US20040151718 Cell surface molecule mediating cell adhesion and signal transmission |
| 08/05/2004 | US20040151716 use of an agent which is capable of disrupting a microbial biofilm; may be a physical agent such as sonic energy or an electrical field, or a chemical agent such as guaifenesin; may also contain an antimicrobial compound |
| 08/05/2004 | US20040151715 Catalytic domain of ADAM33 and methods of use thereof |
| 08/05/2004 | US20040151714 Method for treating elevated intraocular pressure, including glaucoma |
| 08/05/2004 | US20040151712 Modulation of inflammation related to columnar epithelia |
| 08/05/2004 | US20040151710 Topical composition for treating infectious conditions of skin and mucosa |
| 08/05/2004 | US20040151709 Composition and method of creating, regenerating and repairing tissues using a cell-carrying biological implant which is enriched with a platelet concentrate and supplements |
| 08/05/2004 | US20040151707 Vascular cells genetically altered to over-express angiogenic proliferation and maturation factors; treatment of atherosclerosis using same |
| 08/05/2004 | US20040151694 treating multiple sclerosis, rheumatoid arthritis, diabetes mellitus, psoriasis, organ-specific auto-immune diseases, chronic inflammatory demyelinating polyradiculoneuropathy and Guillain-Barre syndrome |
| 08/05/2004 | US20040151693 Use of mullerian inhibiting substance and interferon for treating tumors |
| 08/05/2004 | US20040151692 administering a substance that can activate CD163 to stimulate the growth, proliferation, differentiation and/or mobilization of a stem cell, e.g., a substance that binds CD163 includes antibodies and CD163 ligands. |
| 08/05/2004 | US20040151669 Lymph cells detected by monoclonal antibodies; diagnosis of autoimmune disease, antiallergens |
| 08/05/2004 | DE10303974A1 Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung Amyloid-β (1-42) oligomers, processes for their preparation and their use |
| 08/05/2004 | DE10303672A1 Verwendung eines Neuropeptide und Steroide enthaltenden Gemisches zur Behandlung von Störungen des psychosozialen Erlebens und Verhaltens Use of a mixture containing neuropeptides and steroids for the treatment of disorders of psychosocial experience and behavior |
| 08/05/2004 | CA2802143A1 Cancer therapy sensitizer |
| 08/05/2004 | CA2518888A1 Method for inhibition of necrosis induced by neurotrophin |
| 08/05/2004 | CA2514305A1 A hybrid vector system for use as a vaccine |
| 08/05/2004 | CA2514108A1 Drugs containing galectin 9 |
| 08/05/2004 | CA2513904A1 Protein domain related to deafness, osteoarthritis and abnormal cell proliferation |
| 08/05/2004 | CA2513797A1 Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
| 08/05/2004 | CA2513714A1 Medicament and use thereof for tumor therapy |
| 08/05/2004 | CA2513711A1 Process for the preparation of hypoallergenic mosaic antigens |
| 08/05/2004 | CA2513623A1 Compositions and methods for sirna inhibition of icam-1 |
| 08/05/2004 | CA2513584A1 The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors |
| 08/05/2004 | CA2513571A1 The use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| 08/05/2004 | CA2513331A1 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
| 08/05/2004 | CA2513320A1 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| 08/05/2004 | CA2513308A1 Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods |
| 08/05/2004 | CA2513044A1 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| 08/05/2004 | CA2512824A1 Improved oral delivery of peptides |
| 08/05/2004 | CA2512709A1 Use of tff2, or agents inducing tff2, in the therapy of allergies |
| 08/05/2004 | CA2506855A1 Mntf peptides and compositions and methods of use |
| 08/05/2004 | CA2488677A1 Method of inhibiting prostate cancer cell proliferation |
| 08/04/2004 | EP1443112A2 Macrophage activating factors derived from cloned vitamin D binding protein |
| 08/04/2004 | EP1443110A2 Human VEGF-specific antisense oligonucleotides |
| 08/04/2004 | EP1443056A1 IL-6 receptor.IL-6 direct fusion protein |
| 08/04/2004 | EP1443053A1 Analgesic antitumor peptide from scorpion and method of producing it |
| 08/04/2004 | EP1443051A2 Sugar modified oligonucleotides that detect and modulate gene expression |
| 08/04/2004 | EP1442750A1 Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor |
| 08/04/2004 | EP1442748A1 Use of FSH for treating infertility |
| 08/04/2004 | EP1442747A1 Superoxide dismutase and mimetics thereof |
| 08/04/2004 | EP1442746A1 Stable solid formulation of enalapril salt and process for preparation thereof |
| 08/04/2004 | EP1442744A2 Use of EP4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer |
| 08/04/2004 | EP1442743A1 Medicament comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin converting enzyme (ACE) for use in the treatment of neurodegenerative diseases |
| 08/04/2004 | EP1442741A1 Compositions and methods for treating obesity |
| 08/04/2004 | EP1442297A2 Methods for screening osteogenic compounds |
| 08/04/2004 | EP1442143A2 RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/04/2004 | EP1442140A2 Antisense modulation of insulin-like growth factor binding protein 5 expression |
| 08/04/2004 | EP1442132A2 Methods for the treatment of osteoarthritis and compositions thereof |
| 08/04/2004 | EP1442121A2 Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents |
| 08/04/2004 | EP1442119A2 A mammalian mucinase, its recombinant production, and its use in therapy or prophylaxis against diseases in which mucus is involved or infectious diseases |
| 08/04/2004 | EP1442064A2 Kinases and phosphatases |
| 08/04/2004 | EP1442060A2 A novel g protein-coupled receptor, gave 10 |
| 08/04/2004 | EP1442059A2 Analogs of human growth hormone-releasing hormone, their preparation and use |
| 08/04/2004 | EP1442058A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 08/04/2004 | EP1442051A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 08/04/2004 | EP1442050A2 Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 08/04/2004 | EP1442049A2 Substituted amino ketone compounds |
| 08/04/2004 | EP1442046A2 Mammalian c-type lectins |
| 08/04/2004 | EP1442022A2 Polyamide modulators of cox2 transcription |
| 08/04/2004 | EP1441771A1 Aqueous sustained-release formulations of proteins |
| 08/04/2004 | EP1441764A2 Antigen arrays comprising rankl for treatment of bone disease |
| 08/04/2004 | EP1441757A2 Non-neurotoxic plasminogen activating factors for treating stroke |
| 08/04/2004 | EP1441756A1 Psp-94: use for treatment of hypercalcemia and bone metastasis |
| 08/04/2004 | EP1441755A2 Topical use of cytokines and chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases |
| 08/04/2004 | EP1441754A1 Use of egf to inhibit pathogenic infections of the urogenital tract |
| 08/04/2004 | EP1441753A2 Cell cycle progression proteins |
| 08/04/2004 | EP1441752A1 Endophilin homologous proteins involved in the regulation of energy homeostasis |
| 08/04/2004 | EP1441751A1 TARGETING THE REVERSE MODE OF THE Na+ /Ca2+ EXCHANGER FOR THE TREATMENT OF OPTIC NEUROPATHY ASSOCIATED WITH GLAUCOMA AND ISCHEMIC OPTIC NEUROPATHY |
| 08/04/2004 | EP1441750A2 Linear and cyclic melanocortin receptor-specific peptides |
| 08/04/2004 | EP1441749A2 Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same |
| 08/04/2004 | EP1441748A2 High-concentration protein formulations and method of manufacture |
| 08/04/2004 | EP1441747A2 Use of an extract from the vigna aconitifolia plant in a cosmetic and/or dermopharmaceutical composition |
| 08/04/2004 | EP1441742A2 Axon repair |
| 08/04/2004 | EP1441740A2 Antisense modulation of matrix metalloproteinase 1 expression |
| 08/04/2004 | EP1441738A1 A combination product comprising melagatran and dexamethasone |
| 08/04/2004 | EP1441720A1 Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system |
| 08/04/2004 | EP1441717A1 Combination of an atp-competitive inhibitor of bcr/abl kinase activity and a tyrphostin analog |
| 08/04/2004 | EP1441708A1 Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism |
| 08/04/2004 | EP1441697A2 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| 08/04/2004 | EP1441696A1 Method and composition for dry eye treatment |
| 08/04/2004 | EP1441684A2 Methods and compositions for treating urological disorders using 313, 333, 5464, 18817 or 33524 |
| 08/04/2004 | EP1441682A1 Method to induce neovascular formation and tissue regeneration |